CorMedix Therapeutics Q3 Revenue Falls to $54.5M; FY Guidance Maintained
Q3 2026 revenue was $54.5M versus $104.3M in Q3 2025; net loss was $14.7M versus net income of $108.6M. The company maintained FY 2026 revenue guidance and narrowed Adjusted EBITDA guidance.Material DetailsContext by AI AnalystThis is a quarterly results update showing a sharp year-over-year revenu…